Comparison of baseline, clinical, analytical and radiological characteristics of COVID-19 patients developing acute (myo)pericarditis with respect to COVID-19 patients not developing acute (myopericarditis) |
Chest pain | 13.346 | 7.331 to 24.30 |
Bilirubin>1 mg/dL | 4.455 | 2.045 to 9.701 |
Cardiomegaly in CXR | 3.280 | 1.710 to 6.270 |
Pleural effusion in CXR | 3.120 | 1.250 to 7.770 |
Age <40 years | 3.049 | 1.647 to 5.650 |
Abdominal pain | 2.903 | 1.234 to 6.826 |
Leucocyte count >×109 cells/L) | 2.187 | 1.205 to 3.969 |
Platelet count >300×109 elements/L) | 2.181 | 1.149 to 4.138 |
Pulse oximetry at ED arrival <96% | 0.573 | 0.329 to 0.996 |
C-reactive protein >5 mg/dL | 0.549 | 0.311 to 0.969 |
Dyslipidaemia | 0.479 | 0.251 to 0.915 |
Cough | 0.450 | 0.263 to 0.770 |
Fever >38°C | 0.294 | 0.167 to 0.519 |
Ground-glass lung opacities in CXR | 0.241 | 0.131 to 0.442 |
Dementia | 0.154 | 0.021 to 1.150 |
Comparison of baseline, clinical, analytical and radiological characteristics of COVID-19 patients developing acute (myo)pericarditis with respect to non-COVID patients developing acute (myo)pericarditis
|
Lung interstitial infiltrates in CXR | 16.33 | 7.035 to 37.92 |
Dysgeusia | 15.66 | 1.603 to 152.9 |
Ground-glass lung opacities in CXR | 12.61 | 5.125 to 31.04 |
Anosmia | 10.28 | 0.918 to 115.0 |
Cough | 5.436 | 2.973 to 9.937 |
Lactate dehydrogenase >300 U/L | 4.442 | 1.928 to 10.24 |
Abdominal pain | 3.844 | 1.571 to 9.404 |
Vomiting | 3.844 | 1.571 to 9.404 |
Expectoration | 3.792 | 1.389 to 10.35 |
Tachypnoea >20 bpm | 3.379 | 1.844 to 6.192 |
Dyspnoea | 3.026 | 1.770 to 5.174 |
Length of symptoms >7 days | 2.890 | 1.565 to 5.348 |
Lymphocyte count <1 (x109 cells/L) | 2.878 | 1.603 to 5.165 |
Aspartate aminotransferase >40 U/L | 2.559 | 1.242 to 5.274 |
Fever >38°C | 2.316 | 1.270 to 4.224 |
Tachycardia >100 bpm | 1.819 | 1.017 to 3.254 |
Age <40 years | 0.600 | 0.340 to 1.057 |
Chest pain | 0.379 | 0.185 to 0.777 |
Active smoker | 0.220 | 0.078 to 0.624 |